Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats (British Journal of Pharmacology (2008) 153: 5 (1072-1084) doi:10.1038/sj.bjp.0707643);Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 1072-1084

  Huntjens, D R H ^a   Strougo, A ^a   Chain, A ^a   Metcalf, A ^b   Summerfield, S ^b   Spalding, D J M ^b   Danhof, M ^a   Della Pasqua, O ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

COX 2 inhibitors; Diclofenac; Enterohepatic recirculation; NONMEM; Pharmacokinetics; PKPD modelling; Rofecoxib

Indexed keywords

DICLOFENAC; PROSTAGLANDIN E2; ROFECOXIB;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; EXPERIMENTAL MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 40149095762     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.105     Document Type: Erratum

References (32)

1. Alvarez‐Bujidos L, Ortiz AI, Molina‐Martinez IT, Cubria C, Ordonez D (1998). Pharmacokinetics of intravenous luxabendazole in rabbits: influence of the enterohepatic circulation. Biopharm Drug Dispos 19: 341–347.
2. Baillie TA, Halpin RA, Matuszewski BK, Geer LA, Chavez‐Eng CM, Dean D et al. (2001). Mechanistic studies on the reversible metabolism of rofecoxib to 5‐hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2‐furanone derivative using stable isotope‐labeling techniques. Drug Metab Dispos 29: 1614–1628.
3. Beal SL, Sheiner LB (1999). NONMEM User's Guide. NONMEM Project Group, University of California at San Fransisco: San Fransisco, CA.
4. Bressolle F, Gomeni R (1998). Predictive performance of a semiparametric method to estimate population pharmacokinetic parameters using NONMEM. J Pharmacokinet Biopharm 26: 349–361.
5. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D et al. (1999). Rofecoxib [Vioxx, MK‐0966; 4‐(4′‐methylsulfonylphenyl)‐3‐phenyl‐2‐(5H)‐furanone]: a potent and orally active cyclooxygenase‐2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551–560.
6. Eeckhoudt SL, Evrard PA, Verbeeck RK (1997). Biliary excretion and enterohepatic cycling of R‐ and S‐flurbiprofen in the rat. Drug Metab Dispos 25: 428–430.
7. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA et al. (2005). Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2. Br J Pharmacol 144: 538–550.
8. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK (2001). A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23: 871–885.
9. Fattinger KE, Verotta D (1995). A nonparametric subject‐specific population method for deconvolution: I. Description, internal validation, and real data examples. J Pharmacokinet Biopharm 23: 581–610.
10. Fukuyama T, Yamaoka K, Ohata Y, Nakagawa T (1994). A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. Drug Metab Dispos 22: 479–485.
11. Giagoudakis G, Markantonis SL (1998). An alternative high‐performance liquid chromatographic method for the determination of diclofenac and flurbiprofen in plasma. J Pharm Biomed Anal 17: 897–901.
12. Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN et al. (2000). The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase‐2 inhibitor, in rats and dogs. Drug Metab Dispos 28: 1244–1254.
13. Holford NH, Sheiner LB (1981). Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng 5: 273–322.
14. Jett MF, Ramesha CS, Brown CD, Chiu S, Emmett C, Voronin T et al. (1999). Characterization of the analgesic and anti‐inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 288: 1288–1297.
15. Menasse R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallman A et al. (1978). Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 22 (Suppl): 5–16.
16. Moriwaki T, Yasui H, Yamamoto A (2003). A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference. J Pharmacokinet Pharmacodyn 30: 119–144.
17. Ogiso T, Kitagawa T, Iwaki M, Tanino T (1997). Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics. Biol Pharm Bull 20: 405–410.
18. Park K, Verotta D, Blaschke TF, Sheiner LB (1997). A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm 25: 615–642.
19. Peris‐Ribera JE, Torres‐Molina F, Garcia‐Carbonell MC, Aristorena JC, Pla‐Delfina JM (1991). Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm 19: 647–665.
20. Ploeger BA, Meulenbelt J, DeJongh J (2000). Physiologically based pharmacokinetic modeling of glycyrrhizic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Toxicol Appl Pharmacol 162: 177–188.
21. Priymenko N, Garnier F, Ferre JP, Delatour P, Toutain PL (1998). Enantioselectivity of the enterohepatic recycling of carprofen in the dog. Drug Metab Dispos 26: 170–176.
22. Reuter BK, Davies NM, Wallace JL (1997). Nonsteroidal anti‐inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109–117.
23. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41: 751–790.
24. Schaiquevich P, Niselman A, Rubio M (2002). Comparison of two compartmental models for describing ranitidine's plasmatic profiles. Pharmacol Res 45: 399–405.
25. Seitz S, Boelsterli UA (1998). Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115: 1476–1482.
26. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T (1995). Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal‐venous blood concentrations of diclofenac. Pharm Res 12: 880–883.
27. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T (1996). Local absorption kinetics into the portal system using the portal‐venous concentration difference after an oral dose of diclofenac in the awakening rat. Accelerative effect of bile on intestinal absorption of diclofenac. Drug Metab Dispos 24: 216–220.
28. Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin‐like drugs. Nat New Biol 231: 232–235.
29. Wajima T, Yano Y, Oguma T (2002). A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol 54: 929–934.
30. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999). Nonsteroid drug selectivities for cyclo‐oxygenase‐1 rather than cyclo‐oxygenase‐2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563–7568.
31. Warner TD, Mitchell JA (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790–804.
32. Yano Y, Beal SL, Sheiner LB (2001). Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28: 171–192.